IKT
Income statement / Annual
Last year (2023), Inhibikase Therapeutics, Inc.'s total revenue was $260,500.00,
an increase of 111.03% from the previous year.
In 2023, Inhibikase Therapeutics, Inc.'s net income was -$19.03 M.
See Inhibikase Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$260,500.00
|
$123,440.00
|
$3.10 M
|
$698,468.00
|
$1.12 M
|
$4.04 M
|
$2.06 M
|
$967,386.00
|
| Cost of Revenue |
$13.62 M |
$6,723.00 |
$11.36 M |
$893,802.00 |
$2.55 M |
$3.65 M |
$1.76 M |
$846,386.00 |
| Gross Profit |
-$13.36 M |
$116,717.00 |
-$8.26 M |
-$195,334.00 |
-$1.43 M |
$393,847.00 |
$305,245.00 |
$121,000.00 |
| Gross Profit Ratio |
-51.28 |
0.95 |
-2.66 |
-0.28 |
-1.27 |
0.1 |
0.15 |
0.13 |
| Research and Development
Expenses |
$13.62 M
|
$12.03 M
|
$11.36 M
|
$893,802.00
|
$2.55 M
|
$3.65 M
|
$1.76 M
|
$846,386.00
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.52 M
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.73 M
|
$6.22 M
|
$6.51 M
|
$2.62 M
|
$4.27 M
|
$2.52 M
|
$710,375.00
|
$734,288.00
|
| Other Expenses |
-$13.62 M |
-$123,440.00 |
-$3.10 M |
-$698,468.00 |
-$1.12 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$6.73 M |
$18.13 M |
$14.77 M |
$2.82 M |
$5.70 M |
$2.12 M |
$2.47 M |
$734,287.00 |
| Cost And Expenses |
$20.35 M |
$18.13 M |
$14.77 M |
$2.82 M |
$5.70 M |
$2.12 M |
$2.47 M |
$1.58 M |
| Interest Income |
$1.06 M |
$74,453.00 |
$19,923.00 |
$29,402.00 |
$24,835.00 |
$0.00 |
$30,945.00 |
$15,449.00 |
| Interest Expense |
$0.00 |
$74,453.00 |
$19,923.00 |
$29,402.00 |
$24,835.00 |
$30,332.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$177,398.00
|
$6,723.00
|
$14.77 M
|
$2.82 M
|
$5.70 M
|
$2.12 M
|
$405,130.00
|
$613,288.00
|
| EBITDA |
-$19.91 M
|
-$18.12 M
|
-$14.77 M
|
-$2.82 M
|
-$5.70 M
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA Ratio |
-76.44 |
-146.81 |
-4.76 |
-4.04 |
-5.08 |
-0.53 |
-0.2 |
-0.02 |
| Operating Income Ratio
|
-77.12
|
-146.86
|
-4.76
|
-4.04
|
-5.08
|
-0.53
|
-0.2
|
-0.63
|
| Total Other
Income/Expenses Net |
$1.06 M
|
$74,453.00
|
-$19,923.00
|
-$29,402.00
|
-$24,835.00
|
-$30,332.00
|
-$30,945.00
|
-$15,449.00
|
| Income Before Tax |
-$19.03 M |
-$18.05 M |
-$14.79 M |
-$2.85 M |
-$5.72 M |
-$2.15 M |
-$436,075.00 |
-$628,737.00 |
| Income Before Tax Ratio
|
-73.05
|
-146.26
|
-4.77
|
-4.08
|
-5.1
|
-0.53
|
-0.21
|
-0.65
|
| Income Tax Expense |
$0.00 |
-$148,906.00 |
$19,923.00 |
$29,402.00 |
$24,835.00 |
-$161,141.00 |
-$405,130.00 |
-$15,449.00 |
| Net Income |
-$19.03 M |
-$17.91 M |
-$14.81 M |
-$2.88 M |
-$5.75 M |
-$2.15 M |
-$436,075.00 |
-$628,737.00 |
| Net Income Ratio |
-73.05 |
-145.05 |
-4.78 |
-4.12 |
-5.12 |
-0.53 |
-0.21 |
-0.65 |
| EPS |
-3.57 |
-4.26 |
-4.88 |
-1.72 |
-3.34 |
-1.61 |
-0.25 |
-0.48 |
| EPS Diluted |
-3.57 |
-4.26 |
-4.88 |
-1.72 |
-3.34 |
-1.61 |
-0.25 |
-0.48 |
| Weighted Average Shares
Out |
$5.33 M
|
$4.20 M
|
$3.03 M
|
$1.68 M
|
$1.72 M
|
$1.34 M
|
$1.72 M
|
$1.30 M
|
| Weighted Average Shares
Out Diluted |
$5.33 M
|
$4.20 M
|
$3.03 M
|
$1.68 M
|
$1.72 M
|
$1.34 M
|
$1.72 M
|
$1.30 M
|
| Link |
|
|
|
|
|
|
|
|
